IP2IPO

IP Group, originally founded as IP2IPO, is a leading intellectual property commercialization company that specializes in evolving business ideas from research-intensive universities into world-class companies. The firm operates primarily in the United Kingdom, the United States, and Australasia, providing seed capital, strategic oversight, and business-building expertise. Its portfolio is heavily weighted toward the life sciences, including significant investments in genomics, synthetic biology, and medical diagnostics. Most notably, IP Group was the founding investor in Oxford Nanopore Technologies, demonstrating its ability to scale complex platform technologies from the laboratory to the public markets. The company is listed on the London Stock Exchange and continues to manage a diverse range of spin-outs across biotech, cleantech, and deep tech sectors.